Journal Mobile Options
Table of Contents
Vol. 28, No. 3, 2008
Issue release date: April 2008

Observations on a Cohort of HIV-Infected Patients Undergoing Native Renal Biopsy

Berliner A.R. · Fine D.M. · Lucas G.M. · Rahman M.H. · Racusen L.C. · Scheel P.J. · Atta M.G.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Aims: This study aims to explore the spectrum of renal disease in HIV-infected patients, identify clinical predictors of HIV-associated nephropathy (HIVAN), and investigate the performance of renal biopsy in HIV-infected patients. Method: Of 263 HIV-infected patients with renal disease evaluated between 1995 and 2004, 152 had a renal biopsy, while 111 had not. A group comparison was performed. Results: The leading biopsy diagnoses were HIVAN (35%), noncollapsing focal segmental glomerulosclerosis (22%), and acute interstitial nephritis (7.9%), amongst over a dozen others. There was a trend of decreasing yearly incidence of HIVAN diagnoses, paralleling the use of antiretroviral therapy. By multivariate logistic regression, CD4 counts >200 cells/mm3 and higher estimated glomerular filtration rate were strong negative predictors of HIVAN. HIVAN patients were more likely to require dialysis (p < 0.0001) and had worse overall survival (p = 0.02). Younger age and lower estimated glomerular filtration rate were significant predictors of renal biopsy in multivariate regression analysis. More biopsied patients progressed to dialysis (51 vs. 25%, p = 0.001) and death (15 vs. 5.4%, p = 0.001), despite more frequent corticosteroid treatment (29 vs. 3.6%, p = 0.001). Conclusion: These findings may reflect more severe acute and/or chronic disease at the time of biopsy and suggests that earlier renal biopsy may be warranted in HIV-infected patients, especially in light of the changing spectrum of renal disease in this group.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Rao TK, Filippone EJ, Nicastri AD, Landesman SH, Frank E, Chen CK, Friedman EA: Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984;310:669–673.
  2. Kimmel PL, Barisoni L, Kopp JB: Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann Intern Med 2003;139:214–226.
  3. Schwimmer JA, Markowitz GS, Valeri A, Appel GB: Collapsing glomerulopathy. Semin Nephrol 2003;23:209–218.
  4. Levin ML, Palella F, Shah S, Lerma E, Butter J, Kanwar YS: HIV-associated nephropathy occurring before HIV antibody seroconversion. Am J Kidney Dis 2001;37:E39.
  5. Centers for Disease Control and Prevention (CDC): Epidemiology of HIV/AIDS – United States, 1981–2005. MMWR Morb Mortal Wkly Rep 2006;55:589–592.

    External Resources

  6. Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE: Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005;16:2412–2420.
  7. Gerntholtz TE, Goetsch SJ, Katz I: HIV-related nephropathy: a South African perspective. Kidney Int 2006;69:1885–1891.
  8. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, Fields TA, Svetkey LP, Flanagan KH, Klotman PE, Winston JA: The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004;66:1145–1152.
  9. Atta MG, Choi MJ, Longenecker JC, Haymart M, Wu J, Nagajothi N, Racusen LC, Scheel PJ Jr, Brancati FL, Fine DM: Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy. Am J Med 2005;118:1288.
  10. Atta MG, Longenecker JC, Fine DM, Nagajothi N, Grover DS, Wu J, Racusen LC, Scheel PJ Jr, Hamper UM: Sonography as a predictor of human immunodeficiency virus-associated nephropathy. J Ultrasound Med 2004;23:603–610.
  11. Levey AS, Greene T, Kusek JW, Beck GJ: A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 2000;11:155A.
  12. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD: Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004;18:541–546.
  13. Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, Cohen MH, Anastos K, Klassen PS, Svetkey LP: Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002;61:195–202.
  14. Wali RK, Drachenberg CI, Papadimitriou JC, Keay S, Ramos E: HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 1998;352:783–784.
  15. Scialla JJ, Atta MG, Fine DM: Relapse of HIV-associated nephropathy after discontinuing highly active antiretroviral therapy. AIDS 2007;21:263–264.
  16. Atta MG, Gallant JE, Rahman MH, Nagajothi N, Racusen LC, Scheel PJ, Fine DM: Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006;21:2809–2813.
  17. Han TM, Naicker S, Ramdial PK, Assounga AG: A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 2006;69:2243–2250.
  18. Estrella M, Fine DM, Gallant JE, Rahman MH, Nagajothi N, Racusen LC, Scheel PJ, Atta MG: HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. Clin Infect Dis 2006;43:377–380.
  19. Roling J, Schmid H, Fischereder M, Draenert R, Goebel FD: HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 2006;42:1488–1495.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50